Incretin-based Therapies for Type 2 Diabetes.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Canadian Journal of Diabetes

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1499-2671(08)22010-1PMID 27056542
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vildagliptin

  2012cited by this paper
• Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

  2008cited by this paper
• Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2007cited by this paper
• Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  2007cited by this paper
• Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

  2007cited by this paper
• Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes

  2007cited by this paper
• [Commentary to the article: Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43].

  2007cited by this paper
• Discovery of JANUVIA TM (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes.

  2007cited by this paper
• Nonpeptidic glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes?

  2007cited by this paper
• Dipeptidyl Peptidase-4 Inhibitors

  2007cited by this paper
• beta-cell failure in diabetes and preservation by clinical treatment.

  2007cited by this paper
• Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes

  2007cited by this paper
• The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

  2007cited by this paper
• Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data

  2006cited by this paper
• Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes

  2006cited by this paper
• Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

  2006cited by this paper
• Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.

  2006cited by this paper
• The biology of incretin hormones.

  2006cited by this paper
• Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

  2006cited by this paper
• Diabetes and obesity: the twin epidemics

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.

  2005cited by this paper
• Type 2 diabetes: principles of pathogenesis and therapy

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• The [pre-] history of the incretin concept.

  2005cited by this paper
• PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis.

  2005cited by this paper
• A systematic review of drug therapy to delay or prevent type 2 diabetes.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression*

  2005cited by this paper
• Alpha cell function in health and disease: influence of glucagon-like peptide-1

  2005cited by this paper
• Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

  2005cited by this paper
• What do we know about the secretion and degradation of incretin hormones?

  2005cited by this paper
• The discovery of glucagon-like peptide 1.

  2005cited by this paper
• Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

  2005cited by this paper
• Exenatide: Treatment of type 2 diabetes GLP-1 receptor agonist

  2004cited by this paper
• Encyclopedia of Endocrine Diseases

  2004cited by this paper
• Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.

  2004cited by this paper
• Pharmacological Agents That Directly Modulate Insulin Secretion

  2003cited by this paper
• GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.

  2003cited by this paper
• GLP‐1 derivative liraglutide in rats with β‐cell deficiencies: influence of metabolic state on β‐cell mass dynamics

  2003cited by this paper
• Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV

  2003cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.

  2002cited by this paper
• Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.

  2002cited by this paper
• Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.

  2001cited by this paper
• Pathophysiology and pharmacological treatment of insulin resistance.

  2000cited by this paper
• Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

  1998cited by this paper
• Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

  1998cited by this paper
• Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

  1995cited by this paper
• Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

  1994cited by this paper
• Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

  1993cited by this paper
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper
• Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

  1992cited by this paper
• Gastric Inhibitory Polypeptide

  1982cited by this paper
• The incretin concept today

  1979cited by this paper
• A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides.

  1971cited by this paper
• Sur les possibilites d'un traitement du diabete par I'incretine

  1932cited by this paper

• Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review

  2021cites this paper
• Development of diarylpentadienone analogues as alpha-glucosidase inhibitor: Synthesis, in vitro biological and in vivo toxicity evaluations, and molecular docking analysis.

  2020cites this paper
• Histomorphologie und Pathogenese der diabetischen Nephropathie

  2020cites this paper
• In Silico and In Vitro Assessment of Portuguese Oyster (Crassostrea angulata) Proteins as Precursor of Bioactive Peptides

  2019cites this paper
• EFFECT OF SITAGLIPTIN ON LIPID PROFILE OF TYPE 2 DIABETES MELLITUS PATIENTS

  2019cites this paper
• Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study.

  2016cites this paper
• Genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

  2016cites this paper
• Hyperglycemic and Hypoglycemic Drugs

  2016cites this paper
• The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

  2015cites this paper
• Sitagliptin downregulates retinol-binding protein 4 and upregulates glucose transporter type 4 expression in a type 2 diabetes mellitus rat model.

  2015cites this paper
• Antidiabetic Activity and Phytochemical Screening of Extracts from Indonesian Plants by Inhibition of Alpha Amylase, Alpha Glucosidase and Dipeptidyl Peptidase IV

  2015cites this paper
• The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on.

  2014cites this paper
• ROLE OF ITOPRIDE IN MINIMIZING POST PRANDIAL GLUCOSE EXCURSION IN TYPE 2 DIABETIC PATIENTS

  2014cites this paper
• Association of genetic variants of the incretin-related genes with quantitative traits and occurrence of type 2 diabetes in Japanese

  2014cites this paper
• Incretin hormones and beta-cell mass expansion: what we know and what is missing?

  2013cites this paper
• Dipeptidyl Peptidase-IV: A Brief Review.

  2013cites this paper
• Macrovascular and microvascular complications in type 2 diabetic Iraqi patients treated by metformin and glibenclamide versus metformin and sitagliptin

  2012cites this paper
• Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor

  2012cites this paper
• Incretin Effect in Women with Former Gestational Diabetes within a Short Period after Delivery

  2012cites this paper
• Anti-diabetic effect of a traditional Chinese medicine formula.

  2012cites this paper
• Vildagliptin for the treatment of diabetes

  2011cites this paper
• Therapy in prac T ice

  2011cites this paper
• Tratamiento farmacológico de la prediabetes Pharmacological treatment of prediabetes

  2011cites this paper
• Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

  2010cites this paper
• Incretin agents in type 2 diabetes.

  2010cites this paper
• The Enigma of Tripeptidyl-Peptidase II: Dual Roles in Housekeeping and Stress

  2010cites this paper
• The Therapeutic Role of Incretin Mimetics and DPP-4 Inhibitors

  2009influential citation
• Translating Clinical Trial Data Into New Patterns of Practice

  2009cites this paper
• editorial Advisory Board editor-in-chief Colleen Rand RD CDE editorial Board Members

  2008cites this paper
• Cognitive impairment and diabetes.

  2008cites this paper